These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24701698)

  • 41. A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers.
    Han Y; Lu S; Yu F; Liu X; Sun H; Wang J; Zhu X; Lu H; Yue H; Wang J; Lin J; Zhou C; Tang H; Peng Z
    Sci Rep; 2016 Nov; 6():37240. PubMed ID: 27845412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 43. Is it time to improve colorectal cancer surveillance from 'one size fits all' to personalized care planning?
    Di Fabio F; Moran B
    Colorectal Dis; 2017 Jun; 19(6):525-527. PubMed ID: 28464373
    [No Abstract]   [Full Text] [Related]  

  • 44. Novel antineoplastics targeting genetic changes in colorectal cancer.
    Joudeh J; Allen JE; Das A; Prabhu V; Farbaniec M; Adler J; El-Deiry WS
    Adv Exp Med Biol; 2013; 779():1-34. PubMed ID: 23288633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomics, personalized medicine, and supportive cancer care.
    Sonis ST
    Am Soc Clin Oncol Educ Book; 2015; ():9-16. PubMed ID: 25993135
    [No Abstract]   [Full Text] [Related]  

  • 46. Molecular Triage Trials in Colorectal Cancer.
    O'Hara MH; Hamilton SR; O'Dwyer PJ
    Cancer J; 2016; 22(3):218-22. PubMed ID: 27341602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical colorectal cancer: the epidermal growth factor receptor signaling pathway as a chemotherapeutic target.
    Chu E
    Clin Colorectal Cancer; 2003 Feb; 2(4):202-3. PubMed ID: 12620137
    [No Abstract]   [Full Text] [Related]  

  • 48. Integrating personalised genomics into risk stratification models of population screening for colorectal cancer.
    Cenin D; O'Leary P; Lansdorp-Vogelaar I; Preen D; Jenkins M; Moses E
    Aust N Z J Public Health; 2017 Feb; 41(1):3-4. PubMed ID: 27774701
    [No Abstract]   [Full Text] [Related]  

  • 49. Current trends in clinical genetics of colorectal cancer.
    Markovic S; Dimitrijevic I; Zogovic B; Markovic V; Barisic G; Krivokapic Z
    J BUON; 2016; 21(5):1042-1049. PubMed ID: 27837603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An introduction to stratified medicine.
    Greystoke A; Chaturvedi A
    Drug Discov Today; 2015 Dec; 20(12):1409-13. PubMed ID: 26253659
    [No Abstract]   [Full Text] [Related]  

  • 52. [Oxaliplatin in colorectal cancer].
    Boni C; Banzi M
    Tumori; 2001; 87(1 Suppl 1):S51-2. PubMed ID: 11300025
    [No Abstract]   [Full Text] [Related]  

  • 53. Novel agents in colorectal cancer.
    Erlichman C
    Tumori; 2001; 87(1 Suppl 1):S9. PubMed ID: 11300041
    [No Abstract]   [Full Text] [Related]  

  • 54. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation.
    Weinberg BA; Hartley ML; Salem ME
    Oncology (Williston Park); 2017 Jul; 31(7):573-80. PubMed ID: 28712102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors.
    Overstreet K; Van Cutsem E; Johnson M
    Clin Colorectal Cancer; 2015 Sep; 14(3):131-2. PubMed ID: 26089238
    [No Abstract]   [Full Text] [Related]  

  • 56. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
    Weinberg BA; Hartley ML; Salem ME
    Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.
    Kulesskiy E; Saarela J; Turunen L; Wennerberg K
    J Lab Autom; 2016 Feb; 21(1):27-36. PubMed ID: 26721820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
    Salazar R; Grasselli J; Santos C; Tabernero J
    Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
    [No Abstract]   [Full Text] [Related]  

  • 60. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.
    Palma S; Zwenger AO; Croce MV; Abba MC; Lacunza E
    Clin Colorectal Cancer; 2016 Jun; 15(2):104-15. PubMed ID: 26777471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.